Physician profile
Jiyo Shin
NPI 1922282102
$2,769.64
in general payments reported to CMS, 2019-2025
28 companies · $891 in 2025
The $891 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $154 · 2020: $33.91 · 2021: $12.42 · 2022: $106 · 2023: $961 · 2024: $611 · 2025: $891.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,463.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,463.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $435.54 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $242.65 | 2019-2025 | |
| Glaxosmithkline, LLC. | $191.58 | 2021-2025 | Shingrix, Arexvy |
| Astellas Pharma US INC | $190.32 | 2023-2025 | Veozah |
| Lilly USA, LLC | $157.75 | 2022-2025 | Mounjaro, Jardiance |
| Abbvie INC. | $155.22 | 2023-2025 | Vraylar, Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.89 | 2023-2025 | Jardiance, Ofev |
| Shield Therapeutics INC | $132.00 | 2023-2025 | Accrufer |
| Regeneron Healthcare Solutions, INC. | $127.26 | 2025 | Dupixent |
| Amgen INC. | $105.46 | 2023-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals Lp | $98.79 | 2019-2024 | Breztri, Fasenra |
| Viiv Healthcare Company | $87.91 | 2023-2025 | Apretude |
| Otsuka America Pharmaceutical, INC. | $84.17 | 2023-2024 | Rexulti |
| Dynavax Technologies Corporation | $84.09 | 2023-2025 | Heplisav-B |
| Abbott Laboratories | $61.22 | 2023-2025 | Freestyle Libre 3 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $58.44 | 2023-2024 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $58.38 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $57.39 | 2025 | Neffy |
| Exact Sciences Corporation | $56.33 | 2023-2025 | Cologuard Collection Kit |
| Vanda Pharmaceuticals INC. | $51.98 | 2023 | Hetlioz, Fanapt |
| Sanofi-Aventis U.S. LLC | $43.91 | 2025 | |
| Corium, LLC | $34.71 | 2023 | Azstarys |
| Corcept Therapeutics | $23.79 | 2023 | Korlym |
| Neos Therapeutics, Lp | $22.56 | 2023 | Adzenys Xr-Odt |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.40 | 2024 | Xifaxan |
| Optinose US, INC. | $18.59 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $18.04 | 2024 | Uptravi, Opsumit |
| Merck Sharp & Dohme LLC | $13.27 | 2024 | Gardasil 9, Gardasil, Capvaxive |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jiyo Shin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.